Precise quantification of tumor composition
As patient-derived xenograft (PDX), cell line-derived xenograft (CDX), and transplantable tumor models play strong roles in preclinical cancer research, identifying how much of a sample is of human origin vs. mouse can be key to revealing treatment-related results and choosing tumor fragments with the highest percentage of human tissue for cryopreservation and future passage.
By delivering breakthrough precision in measuring the composition of a mixed cellular population, IDEXX BioAnalytics' patent-pending ConfirmPDX assay provides a comprehensive overview of the genetic makeup of your tumor cells. Your team will always be armed with the data they need to make crucial study decisions.
Easy, one-step sample preparation and submission
ConfirmPDX is the first commercially available test for relative speciation of mixed population samples. And all you have to do is send in a single vial of cells, PDX tumor fragment, formalin-fixed paraffin-embedded tissue block sample, fresh-frozen tumor, or cell line. No advanced labeling is needed, and there’s no new sample preparation to learn. The data you need to drive your next steps confidently will be in your inbox at the speed you depend on from IDEXX BioAnalytics.
Make ConfirmPDX a regular part of your research best practices.
Contact IDEXX BioAnalytics to discuss today.